文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.

作者信息

Scott Sara A, Marin Ellen M, Maples Kathryn T, Joseph Nisha S, Hofmeister Craig C, Gupta Vikas A, Dhodapkar Madhav V, Kaufman Jonathan L, Lonial Sagar, Nooka Ajay K

机构信息

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

出版信息

Blood Cancer J. 2023 Dec 20;13(1):191. doi: 10.1038/s41408-023-00963-y.

DOI:10.1038/s41408-023-00963-y
PMID:38114481
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10730907/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0575/10730907/f6ea739e01c1/41408_2023_963_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0575/10730907/f6ea739e01c1/41408_2023_963_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0575/10730907/f6ea739e01c1/41408_2023_963_Fig1_HTML.jpg

相似文献

[1]
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.

Blood Cancer J. 2023-12-20

[2]
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.

Cancer. 2023-7-1

[3]
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.

Front Immunol. 2021

[4]
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.

Oncologist. 2018-4-5

[5]
Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Hematol Oncol. 2018-2

[6]
Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.

Viruses. 2021-6-3

[7]
Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study.

Semin Oncol Nurs. 2024-6

[8]
Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.

Arch Med Res. 2020-5-21

[9]
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.

Chest. 2020-6-15

[10]
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.

Proc Natl Acad Sci U S A. 2020-8-21

引用本文的文献

[1]
Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada.

Curr Oncol. 2025-8-15

[2]
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma.

Front Oncol. 2025-7-30

[3]
European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.

Eur J Haematol. 2025-10

[4]
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma.

Blood Cancer J. 2025-4-23

[5]
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review.

Cancers (Basel). 2025-4-5

[6]
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study.

Blood Cancer J. 2025-4-3

[7]
Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients.

Drug Saf. 2025-3-19

[8]
Knowledge mapping and visualized analysis of research progress in onconephrology: a bibliometric analysis.

Ren Fail. 2025-12

[9]
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma.

Blood Cancer J. 2025-3-4

[10]
A new era in myeloma: the advent of chimeric antigen receptor-T (CAR-T) cells and bispecific antibodies.

Intern Med J. 2025-5

本文引用的文献

[1]
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.

Blood Adv. 2024-4-9

[2]
Teclistamab in Relapsed or Refractory Multiple Myeloma.

N Engl J Med. 2022-8-11

[3]
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Biol Blood Marrow Transplant. 2018-12-25

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索